Summary Text

SUMMARY: First diagnosed with myeloma October 2011. Recruited onto clinical trial Myeloma X11 (Lenalidomide) at Bristol Oncology and Haematology Centre. First High Dose Therapy and Stem Cell Transplant (HDT&SCT) in July 2012. On maintenance until June 2017. June 2018 recruited onto Myeloma XII trial (Ixazomib). December 2018 Second HDT&SCT. On maintenance until February 2020. August 2020 Commenced treatment involving Daratumumab. April 2021 relapsed. June 2021 recruited onto Cartitude 4 clinical trial and infused with CAR-T cells in October 2021. My own immune system is now fighting the cancer . I am exceedingly fortunate.


Tuesday, 10 November 2020

November Review

I was phoned today by my consultant.  The news was much as expected and not especially good.  Despite having a week off treatment, my platelet count remains stubbornly too low to continue into Cycle 4 treatment.  In addition my haemoglobin count is now giving rise for concern.  He discussed the possibility, once my blood levels have been improved to the level required, I might be recruited into a further trial.  This is most positive although not without some risks.  Looking for good news, my liver and kidney and calcium results remain very good.

Meanwhile I am to have yet another CT scan tomorrow to see what is causing my back pain and whether the myeloma has spread perhaps into my ribs.

Keep safe, keep well and KBO

Stephen